For investors
A defensible platform, real traction, a clear path.
ArrowBiome is a platform (not a product), with clinical proof, foundational MIT-originated IP, an expanding portfolio of ArrowBiome-owned patents, and commercial momentum in a market migrating toward exactly what we make.
47 engagements / 19 markets
Including major global beauty multinationals and leading ingredient houses.
A clear path to profitability
Our base case reaches durable profitability on two commercial products alone, at healthy gross margin, before the platform’s next applications contribute.
Pre-Series A closed, oversubscribed
Closed and oversubscribed against a US$1.9M target. A priced Series A round opens in Q4 2026.
M&A exit logic
~75% of active-ingredient biotechs exit via M&A; comparable microbiome deals at 6–12× revenue.